Literature DB >> 15259754

Prescription-filling rates for key medications in Veterans Affairs patients after coronary artery bypass grafting.

Janice V Huang1, Adrianne W Casebeer, Mary E Plomondon, A Laurie W Shroyer, Gerald O McDonald, David Fullerton, Missy R Bell, Janet Baltz, Frederick L Grover, Francesca Cunningham.   

Abstract

PURPOSE: The six-month prescription-filling rates for key secondary-prevention drugs in Department of Veterans Affairs (VA) patients who had undergone coronary artery bypass grafting (CABG) were studied.
METHODS: Patient records for elective CABG from April 2000 through March 2002 (divided into four six-month periods) were analyzed. The study population included 8925 CABG-only patients surviving to hospital discharge. For each six-month period and in aggregate, the primary study endpoint was the six-month prescription-filling rate.
RESULTS: Across the four six-month periods, prescription-filling rates increased for all categories of medications studied. There were modest progressive increases for lipid-lowering agents, statins, -blockers, angiotensin-converting-enzyme Inhibitors, and angiotensin-receptor blockers. The antithrombotic-filling rate averaged 88.5%. Filling rates for aspirin were much higher than for aspirin alternatives.
CONCLUSION: Prescription-filling rates for post-CABG medications in VA facilities were generally high and suggested compliance with guidelines for the prevention of cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259754     DOI: 10.1093/ajhp/61.12.1248

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  1 in total

1.  Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry.

Authors:  Rajendra H Mehta; Deepak L Bhatt; Ph Gabriel Steg; Shinya Goto; Alan T Hirsch; Chiau-Suong Liau; Joachim Röther; Peter W F Wilson; Alain-Jean Richard; Kim A Eagle; E Magnus Ohman
Journal:  Eur Heart J       Date:  2008-11-07       Impact factor: 29.983

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.